Edmund C. Baracat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edmund C. Baracat has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Leme Alves da Motta
Huntington Medicina Reprodutiva—Eugin Group, São Paulo 04501-000, SP, Brazil
2 shared publications - Ana Lúcia Beltrame
Department of Obstetrics and Gynecology, School of Medicine, University of São Paulo (USP), São Paulo, Brazil
1 shared publication - André Monteiro da Rocha
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
1 shared publication - Gary Daniel Smith
Departments of Obstetrics and Gynecology, Physiology, and Urology, University of Michigan Medical School, Ann Arbor, MI, USA; MStem Cell Laboratories, University of Michigan, Ann Arbor, MI, USA
1 shared publication - Ismael Dcg Silva
Department of Gynecology, Universidade Federal de São Paulo, São Paulo, Brazil
1 shared publication José Maria Soares Júnior
Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil
1 shared publication
Latest Publications
- 20 November 2012
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 29 (3) , 201-204
The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome inin vitrofertilization patients: a pilot study
The aim of this study was to evaluate the effects of bromocriptine on vascular endothelial growth factor (VEGF) levels in serum, kidney function and ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Twenty-eight women were randomly divided into two groups and were administered daily oral capsules for 14 days, starting on the day of human chorionic gonadotropin (hCG) administration. Group A received 2.0 mg of folic acid, whereas Group B was given 2.5 mg of bromocriptine. Physical exams, pelvic ultrasounds and laboratory evaluations were performed on the day of hCG administration and again 7 days later. No differences in ovarian hyperstimulation syndrome, urine volume, creatinine clearance, urine sodium concentration or serum VEGF levels were found between the two groups. Thus, these results indicate that bromocriptine does not affect blood levels of VEGF, kidney function or the incidence of ovarian hyperstimulation syndrome in high-risk patients subjected to in vitro fertilization.
- 20 November 2012
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 29 (3) , 201-204
The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome inin vitrofertilization patients: a pilot study
The aim of this study was to evaluate the effects of bromocriptine on vascular endothelial growth factor (VEGF) levels in serum, kidney function and ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Twenty-eight women were randomly divided into two groups and were administered daily oral capsules for 14 days, starting on the day of human chorionic gonadotropin (hCG) administration. Group A received 2.0 mg of folic acid, whereas Group B was given 2.5 mg of bromocriptine. Physical exams, pelvic ultrasounds and laboratory evaluations were performed on the day of hCG administration and again 7 days later. No differences in ovarian hyperstimulation syndrome, urine volume, creatinine clearance, urine sodium concentration or serum VEGF levels were found between the two groups. Thus, these results indicate that bromocriptine does not affect blood levels of VEGF, kidney function or the incidence of ovarian hyperstimulation syndrome in high-risk patients subjected to in vitro fertilization.
- Open Access
- 19 April 2009
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 7 (1) , 30
Endometrial claudin-4 and leukemia inhibitory factor are associated with assisted reproduction outcome
Claudin-4 (CLDN4) is one of several proteins that act as molecular mediators of embryo implantation. Recently, we examined immunolabeling of leukemia inhibitory factor (LIF) in the endometrial tissue of 52 IVF patients, and found that LIF staining intensity was strongly correlated with successful pregnancy initiation. In the same set of patients, we have now examined endometrial CLDN4 expression, to see how expression intensity may vary with LIF. We examined CLDN4 in the luteal phase of the menstrual cycle, immediately preceding IVF treatment. Our aim was to compare expression of LIF and CLDN4 in the luteal phase, and document these patterns as putative biomarkers for pregnancy.
- 19 April 2009
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 7 (1) , 30
Open AccessEndometrial claudin-4 and leukemia inhibitory factor are associated with assisted reproduction outcome
Claudin-4 (CLDN4) is one of several proteins that act as molecular mediators of embryo implantation. Recently, we examined immunolabeling of leukemia inhibitory factor (LIF) in the endometrial tissue of 52 IVF patients, and found that LIF staining intensity was strongly correlated with successful pregnancy initiation. In the same set of patients, we have now examined endometrial CLDN4 expression, to see how expression intensity may vary with LIF. We examined CLDN4 in the luteal phase of the menstrual cycle, immediately preceding IVF treatment. Our aim was to compare expression of LIF and CLDN4 in the luteal phase, and document these patterns as putative biomarkers for pregnancy.